Drug details

Fotivda (tivozanib capsules)

type of Antineoplastics, VEGF Inhibitor

Fotivda (tivozanib) is a kinase inhibitor indicated for the treatment of adult patients with relapsed or refractory advanced renal cell carcinoma (RCC) following two or more prior systemic therapies.

This drug may have the following side effects:

• nausea,
• rash,
• vomiting,
• diarrhea,
• shortness of breath,
• weight loss,
• back pain,
• fatigue,
• cough,
• bleeding,
• hoarseness,
• high blood pressure (hypertension),
• decreased appetite,
• decreased phosphate
• hypothyroidism,
• inflammation of the mouth and lips,
• decreased sodium,
• increased lipase,

The following drugs are related to Fotivda, either as a replacement or used together:

• Afinitor (everolimus tablets)
• Afinitor Disperz (everolimus tablets)
• Avastin (bevacizumab)
• Bavencio (avelumab injection)
• Inlyta (axitinib)
• Welireg (belzutifan tablets)
• Mvasi (bevacizumab-awwb solution for intravenous infusion)
• Zirabev (bevacizumab-bvzr injection)
• Cabometyx (cabozantinib tablets)
• Jelmyto (mitomycin for pyelocalyceal solution)
• Keytruda (pembrolizumab for injection)
• Lenvima (lenvatinib capsules)
• Nexavar (sorafenib)
• Opdivo (nivolumab injection)
• Votrient (pazopanib tablets)
• Zynyz (retifanlimab-dlwr)